
  
    
      
        Background_NNP
        High_JJ levels_NNS of_IN serum_NN cholesterol_NN and_CC low_JJ density_NN
        lipoprotein_NN (_( LDL_NNP )_) have_VBP been_VBN associated_VBN with_IN the_DT genesis_NN of_IN
        atherosclerosis_NNS ,_, a_DT leading_VBG cause_NN of_IN cardiovascular_JJ diseases_NNS
        that_WDT affect_VBP a_DT large_JJ number_NN of_IN people_NNS all_DT over_IN the_DT world_NN ._. It_PRP
        has_VBZ become_VBN clear_JJ that_IN the_DT pathological_JJ conditions_NNS
        associated_VBN with_IN an_DT excess_JJ level_NN of_IN LDL_NNP are_VBP actually_RB caused_VBN
        by_IN the_DT oxidized_JJ products_NNS of_IN LDL_NNP [_NN 1_CD ]_NN ._. More_RBR specifically_RB ,_,
        cholesterol_NN oxides_NNS (_( also_RB termed_VBD oxysterols_NNS )_) ,_, the_DT oxygenated_JJ
        derivatives_NNS of_IN cholesterol_NN ,_, appear_VB to_TO be_VB the_DT major_JJ
        cytotoxic_JJ components_NNS in_IN oxidized_JJ LDL_NNP [_NN 2_CD 3_CD ]_NN ._. These_DT
        compounds_NNS have_VBP a_DT hydroxyl-_NN or_CC a_DT keto-_NN group_NN on_IN the_DT
        cholesterol_NN molecule_NN ._. Examples_NNS of_IN cholesterol_NN oxides_NNS
        include_VBP :_: 7_CD -_: OH-_NNP ,_, 7_CD -_: keto-_NN ,_, 19_CD -_: OH-_NNP ,_, 22_CD -_: OH-_NNP and_CC
        25_CD -_: OH-cholesterol_NNP (_( see_VB [_NN 4_CD ]_NN for_IN a_DT recent_JJ review_NN )_) ._.
        Tissue_NNP damage_NN caused_VBN by_IN cholesterol_NN oxides_NNS has_VBZ been_VBN the_DT
        subject_NN of_IN many_JJ studies_NNS ._. Cholesterol_NNP oxides_NNS are_VBP cytotoxic_JJ
        to_TO a_DT variety_NN of_IN cell_NN types_NNS [_NN 5_CD ]_NN ._. These_DT compounds_NNS can_MD
        damage_VB endothelial_NN cells_NNS ,_, smooth_JJ muscle_NN cells_NNS and_CC
        fibroblasts_NNS ,_, all_DT of_IN which_WDT are_VBP major_JJ components_NNS of_IN the_DT
        arterial_NN wall_NN ._. Cholesterol_NNP oxides_NNS are_VBP also_RB toxic_JJ to_TO cells_NNS
        derived_VBN from_IN the_DT immune_JJ system_NN ,_, such_JJ as_IN macrophages_NNS ,_,
        thymocytes_NNS ,_, lymphoma_NN cells_NNS and_CC leukemic_JJ T-_NNP cells_NNS ._.
        Pharmacological_NNP agents_NNS capable_JJ of_IN reducing_VBG cholesterol_NN
        oxide_NN toxicity_NN are_VBP yet_RB to_TO be_VB discovered_VBN ._.
        The_DT mode_NN of_IN cell_NN death_NN caused_VBN by_IN cholesterol_NN oxides_NNS has_VBZ
        generated_VBN much_JJ interest_NN recently_RB ._. There_EX is_VBZ evidence_NN showing_VBG
        that_WDT programmed_VBN cell_NN death_NN (_( PCD_NNP ,_, also_RB known_VBN as_IN apoptosis_NNS )_)
        occurs_VBZ in_IN some_DT cells_NNS treated_VBN with_IN cholesterol_NN oxides_NNS [_NN 6_CD 7_CD
        8_CD ]_NN ._. PCD_NNP is_VBZ a_DT special_JJ type_NN of_IN cell_NN death_NN that_WDT can_MD be_VB
        induced_VBN by_IN growth_NN factor_NN deprivation_NN or_CC toxins_NNS [_NN 9_CD 10_CD 11_CD ]_NN
        ._. By_IN using_VBG the_DT PCD_NNP induced_VBN by_IN nerve_NN growth_NN factor_NN
        deprivation_NN in_IN sympathetic_JJ neurons_NNS as_IN an_DT example_NN ,_, the_DT cell_NN
        death_NN process_NN begins_VBZ with_IN the_DT generation_NN of_IN reactive_JJ oxygen_NN
        species_NNS followed_VBN by_IN a_DT significant_JJ decrease_NN in_IN glucose_NN
        uptake_NN ,_, RNA_NNP and_CC protein_NN synthesis_NN ,_, activation_NN of_IN the_DT
        immediate_JJ early_JJ protein_NN ,_, c-jun_JJ ,_, and_CC release_NN of_IN cytochrome_NN c_SYM
        from_IN mitochondria_NN ._. Cell_NNP death_NN is_VBZ executed_VBN by_IN the_DT activation_NN
        of_IN a_DT family_NN of_IN proteases_NNS termed_VBD caspases_NNS ._. Morphologically_NNP ,_,
        cells_NNS dying_VBG of_IN PCD_NNP appear_VB atrophic_JJ and_CC exhibit_VB condensed_JJ
        nuclei_NN ,_, which_WDT can_MD be_VB stained_JJ with_IN nuclear_JJ stains_NNS
        (_( bisbenzimide_NN or_CC propidium_NN iodide_NN )_) ,_, or_CC by_IN the_DT TUNEL_NNP assay_NN ._.
        DNA_NNP extracted_VBD from_IN cells_NNS dying_VBG of_IN PCD_NNP is_VBZ often_RB fragmented_JJ
        and_CC shows_VBZ a_DT characteristic_JJ ladder-type_JJ pattern_NN on_IN the_DT
        agarose_NN gel_NN upon_IN electrophoresis_NNS ._.
        MAP_NNP kinases_NNS (_( Mitogen-_NNP Activated_NNP Protein_NNP kinases_NNS )_) have_VBP
        very_RB important_JJ roles_NNS in_IN PCD_NNP ._. The_DT MAP_NNP kinase_NN pathway_NN
        consists_VBZ of_IN 3_CD major_JJ parallel_JJ pathways_NNS designated_VBN as_IN the_DT ERK_NNP
        (_( p_NN 42_CD /_NN 44_CD ,_, Extracellular_NNP signal-_NN Regulated_NNP Kinase_NNP )_) ,_, SAPK_NNP /_NN JNK_NNP
        (_( p_NN 46_CD ,_, Stress-_NNP Activated_NNP Protein_NNP Kinase_NNP /_NN c-_NN Jun_NNP NH_NNP 2_CD -_: terminal_NN
        Kinase_NNP )_) and_CC p_NN 38_CD pathways_NNS [_NN 12_CD 13_CD 14_CD ]_NN ._. Activation_NNP of_IN each_DT
        pathway_NN above_IN involves_VBZ phosphorylation_NN of_IN a_DT number_NN of_IN
        upstream_RB and_CC downstream_JJ family_NN members_NNS of_IN the_DT pathway_NN ._.
        During_IN growth_NN factor_NN deprivation_NN induced_VBD PCD_NNP in_IN neuronal_NN
        PC_NN 12_CD cells_NNS ,_, there_EX is_VBZ a_DT sustained_VBN activation_NN of_IN the_DT JNK_NNP and_CC
        p_NN 38_CD pathways_NNS while_IN the_DT activities_NNS of_IN ERK_NNP pathway_NN is_VBZ
        inhibited_VBD ._. It_PRP was_VBD proposed_VBN that_IN a_DT dynamic_JJ balance_NN of_IN
        JNK-p_NNP 38_CD and_CC ERK_NNP can_MD determine_VB if_IN the_DT neuronal_NN cell_NN will_MD
        live_VB or_CC die_VB [_NN 15_CD ]_NN ._. Similar_JJ interplay_NN of_IN the_DT MAP_NNP kinases_NNS
        was_VBD shown_VBN in_IN the_DT PCD_NNP of_IN non-neuronal_JJ cells_NNS [_NN 16_CD ]_NN ._. It_PRP is_VBZ
        known_VBN that_IN oxidized_JJ LDL_NNP can_MD cause_VB activation_NN of_IN MAP_NNP kinases_NNS
        [_NN 17_CD 18_CD ]_NN ._. Whether_IN cholesterol_NN oxides_NNS ,_, the_DT main_JJ toxic_JJ
        components_NNS in_IN oxidized_JJ LDL_NNP ,_, can_MD induce_VB MAP_NNP kinase_NN
        activation_NN ,_, and_CC whether_IN MAP_NNP kinase_NN activation_NN has_VBZ a_DT role_NN in_IN
        cholesterol_NN oxide_NN induced_VBD PCD_NNP remain_VBP to_TO be_VB investigated_VBN ,_,
        and_CC is_VBZ the_DT subject_NN of_IN this_DT study_NN ._.
        Peroxisome_NNP proliferator-activated_JJ receptors_NNS (_( PPARs_NNP )_)
        belong_VB to_TO a_DT group_NN of_IN nuclear_JJ receptors_NNS which_WDT includes_VBZ
        steroid_NN ,_, retinoid_NN ,_, thyroid_NN hormone_NN receptors_NNS and_CC others_NNS [_NN
        19_CD 20_CD 21_CD ]_NN ._. There_EX are_VBP three_CD types_NNS of_IN PPARs_NNP :_: PPARα_NNP is_VBZ found_VBN
        predominantly_RB in_IN the_DT liver_NN ,_, heart_NN ,_, kidney_NN ,_, brown_JJ adipose_NN
        and_CC stomach_NN mucosa_NN ,_, and_CC is_VBZ important_JJ for_IN lipid_NN catabolism_NN ._.
        PPARγ_NNP is_VBZ found_VBN in_IN adipose_NN tissues_NNS ,_, and_CC is_VBZ important_JJ for_IN
        adipogenesis_NNS ._. PPARβ_NNP is_VBZ found_VBN in_IN most_JJS tissues_NNS ,_, but_CC its_PRP$ role_NN
        is_VBZ less_RBR well-defined_JJ ._.
        PPARγ_NNP is_VBZ expressed_VBN in_IN atherosclerotic_JJ lesions_NNS [_NN 22_CD ]_NN and_CC
        is_VBZ important_JJ in_IN the_DT process_NN of_IN atherogenesis_NNS ._. Depending_VBG on_IN
        the_DT experimental_JJ system_NN and_CC the_DT particular_JJ question_NN asked_VBD ,_,
        PPARγ_NNP can_MD be_VB involved_VBN with_IN pro-atherogenesis_JJ or_CC
        anti-atherogenesis_JJ ._. For_IN example_NN ,_, PPARγ_NNP is_VBZ involved_VBN in_IN a_DT
        positive_JJ feedback_NN mechanism_NN that_WDT induces_VBZ the_DT formation_NN of_IN
        foam_NN cells_NNS [_NN 23_CD ]_NN ._. On_IN the_DT other_JJ hand_NN ,_, activation_NN of_IN PPARγ_NNP
        was_VBD shown_VBN to_TO inhibit_VB monocyte_NN [_NN 24_CD ]_NN and_CC macrophage_NN [_NN 25_CD ]_NN
        inflammatory_JJ responses_NNS by_IN preventing_VBG the_DT activation_NN of_IN
        nuclear_JJ transcription_NN factors_NNS ,_, such_JJ as_IN NF-kB_NNP (_( nuclear_JJ
        factor-kappa_JJ B_NNP )_) ,_, AP-_NNP 1_CD (_( activator_NN protein-_NN 1_LS )_) and_CC STAT_NNP 1_CD
        (_( signal_NN transducer_NN and_CC activator_NN of_IN transcription_NN 1_LS )_) ._. Since_IN
        inflammation_NN plays_VBZ an_DT important_JJ role_NN in_IN atherogenesis_NNS ,_, this_DT
        anti-inflammatory_JJ effect_NN of_IN PPARγ_NNP should_MD help_VB to_TO reduce_VB the_DT
        risk_NN of_IN atherogenesis_NNS ._. Development_NNP of_IN PPAR_NNP agonists_NNS that_WDT
        retain_VBP the_DT antiatherogenic_JJ activity_NN but_CC dismiss_VB the_DT
        proatherogenic_JJ activities_NNS will_MD be_VB of_IN great_JJ value_NN [_NN 26_CD ]_NN
        ._.
        Many_JJ naturally_RB occurring_VBG or_CC synthetic_JJ compounds_NNS are_VBP
        agonists_NNS for_IN the_DT PPARs_NNP [_NN 20_CD 21_CD ]_NN ._. For_IN example_NN ,_, a_DT number_NN of_IN
        prostaglandins_NNS are_VBP agonists_NNS for_IN PPARγ_NNP ._. The_DT prostaglandin_NN ,_,
        15_CD -_: deoxy-delta_JJ 12_CD ,_, 14_CD -_: PGJ_NNP 
        2_CD (_( 15_CD d-_NN PGJ_NNP 
        2_LS )_) ,_, is_VBZ the_DT most_RBS potent_JJ endogenous_JJ PPARγ_NNP
        agonist_NN known_VBN ._. On_IN the_DT other_JJ hand_NN ,_, many_JJ synthetic_JJ compounds_NNS
        such_JJ as_IN the_DT non-steroid_JJ anti-inflammatory_JJ drugs_NNS (_( NSAIDs_NNP )_)
        are_VBP PPARα_NNP and_CC PPARγ_NNP agonists_NNS [_NN 27_CD ]_NN ._. Since_IN these_DT are_VBP
        agents_NNS used_VBN clinically_RB for_IN other_JJ purposes_NNS ,_, it_PRP is_VBZ important_JJ
        to_TO determine_VB whether_IN interaction_NN of_IN these_DT agents_NNS with_IN PPARs_NNP
        could_MD modulate_VBP atherogenesis_NNS in_IN a_DT positive_JJ or_CC negative_JJ
        manner_NN ._.
        While_IN most_JJS research_NN regarding_VBG cholesterol_NN oxides_NNS are_VBP
        focused_VBN on_IN the_DT cardiovascular_JJ system_NN ,_, it_PRP should_MD be_VB noted_VBN
        that_IN the_DT nervous_JJ tissue_NN has_VBZ the_DT ability_NN to_TO generate_VB
        cholesterol_NN oxides_NNS ,_, which_WDT may_MD exert_VB toxic_JJ effect_NN on_IN cells_NNS
        and_CC tissues_NNS of_IN the_DT nervous_JJ system_NN ._. For_IN example_NN ,_, it_PRP has_VBZ been_VBN
        shown_VBN that_IN synaptosomes_NNS and_CC mitochondria_NN prepared_VBN from_IN CNS_NNP
        tissue_NN can_MD convert_VB cholesterol_NN to_TO cholesterol_NN oxides_NNS ,_, which_WDT
        may_MD play_VB an_DT important_JJ role_NN in_IN brain_NN tissue_NN damage_NN during_IN
        oxidative_JJ stress_NN [_NN 28_CD ]_NN ._. Consistent_NNP with_IN this_DT notion_NN ,_, we_PRP
        have_VBP shown_VBN cholesterol_NN oxides_NNS are_VBP toxic_JJ to_TO neuronal_NN PC_NN 12_CD
        cells_NNS [_NN 29_CD 30_CD ]_NN and_CC neurons_NNS derived_VBN from_IN sympathetic_JJ
        ganglia_NN [_NN 31_CD ]_NN ,_, retina_NN [_NN 32_CD ]_NN and_CC cerebellum_NN [_NN 33_CD ]_NN ._.
        Microglia_NNP in_IN the_DT central_JJ nervous_JJ system_NN express_VB
        scavenger_NN receptors_NNS and_CC are_VBP involved_VBN in_IN the_DT oxidized_JJ LDL_NNP
        uptake_NN and_CC metabolism_NN [_NN 34_CD ]_NN ._. These_DT cells_NNS are_VBP ,_, thus_RB ,_, the_DT
        macrophage-equivalent_JJ in_IN the_DT central_JJ nervous_JJ system_NN [_NN 35_CD ]_NN
        ._. Results_NNS from_IN this_DT laboratory_NN showed_VBD that_IN cholesterol_NN
        oxides_NNS can_MD cause_VB programmed_VBN cell_NN death_NN in_IN microglia_NN [_NN 7_CD ]_NN ,_,
        which_WDT suggests_VBZ that_DT microglia_NN ,_, similar_JJ to_TO macrophages_NNS ,_, can_MD
        be_VB a_DT potential_JJ target_NN for_IN oxidized_JJ LDL_NNP toxicity_NN ._.
        Based_VBN on_IN the_DT observations_NNS that_IN :_: 1_CD ._. cholesterol_NN oxides_NNS
        cause_VBP PCD_NNP but_CC the_DT involvement_NN of_IN MAP_NNP kinases_NNS remains_VBZ to_TO be_VB
        investigated_VBN ;_: 2_CD ._. PPARs_NNP are_VBP important_JJ in_IN atherosclerosis_NNS but_CC
        the_DT effect_NN of_IN PPAR_NNP activation_NN on_IN cholesterol_NN oxide_NN induced_VBD
        PCD_NNP has_VBZ not_RB been_VBN determined_VBN ,_, this_DT study_NN was_VBD designed_VBN to_TO
        test_VB if_IN a_DT dysregulation_NN of_IN MAP_NNP kinases_NNS was_VBD associated_VBN with_IN
        the_DT cholesterol_NN oxide_NN induced_VBD PCD_NNP ,_, and_CC to_TO determine_VB if_IN PPAR_NNP
        activation_NN could_MD modulate_VBP the_DT cholesterol_NN oxide_NN induced_VBD
        PCD_NNP ._.
      
      
        Results_NNS
        
          Cytotoxicity_NNP of_IN 25_CD -_: OH-cholesterol_NNP toward_IN
          microglia_NN
          A_DT set_NN of_IN dose-_NN and_CC time-response_JJ experiments_NNS indicated_VBD
          that_IN 5_CD ,_, 10_CD and_CC 20_CD μM_NN 25_CD -_: OH-cholesterol_NNP treatment_NN for_IN one_CD
          day_NN reduced_VBD the_DT viability_NN to_TO ~_NN 97_CD ,_, 70_CD and_CC 52_CD %_NN of_IN controls_NNS ,_,
          respectively_RB (_( Fig_NNP ._. 1_LS )_) ._. This_DT agent_NN at_IN 5_CD μM_NN reduced_VBD the_DT
          viability_NN to_TO ~_NN 9_CD %_NN of_IN controls_NNS after_IN a_DT 2_CD -_: day_NN treatment_NN ._. In_IN
          contrast_NN ,_, 7_CD -_: β-_NN OH-cholesterol_NNP was_VBD much_RB less_RBR toxic_JJ to_TO
          microglia_NN ,_, such_JJ that_IN this_DT agent_NN at_IN 20_CD μM_NN showed_VBD little_JJ
          toxicity_NN to_TO the_DT cells_NNS after_IN a_DT 1_CD -_: day_NN treatment_NN (_( Fig_NNP ._. 2_LS )_) ._. A_DT
          3_CD -_: day_NN treatment_NN of_IN the_DT cells_NNS with_IN 20_CD μM_NN
          7_CD -_: β-_NN OH-cholesterol_NNP reduced_VBD the_DT viability_NN to_TO ~_NN 81_CD %_NN of_IN
          controls_NNS ._. These_DT results_NNS confirmed_VBD and_CC extended_VBD those_DT
          obtained_VBN from_IN our_PRP$ previous_JJ study_NN [_NN 7_CD ]_NN ._.
        
        
          Activation_NNP of_IN c-jun_JJ as_IN a_DT result_NN of_IN
          25_CD -_: OH-cholesterol_NNP treatment_NN
          Because_IN c-jun_JJ was_VBD shown_VBN to_TO play_VB important_JJ roles_NNS in_IN
          programmed_VBN cell_NN death_NN in_IN many_JJ cell_NN types_NNS [_NN 20_CD 21_CD ]_NN ,_, and_CC
          microglia_NN were_VBD shown_VBN to_TO undergo_VB programmed_VBN cell_NN death_NN
          after_IN cholesterol_NN oxide_NN treatment_NN [_NN 7_CD ]_NN ,_, experiments_NNS
          were_VBD performed_VBN to_TO determine_VB if_IN c-jun_JJ activation_NN was_VBD
          involved_VBN in_IN cholesterol_NN oxide_NN induced_VBD microglial_NN cell_NN
          death_NN ._. Cells_NNP were_VBD treated_VBN with_IN 10_CD μM_NN 25_CD -_: OH-cholesterol_NNP or_CC
          7_CD -_: β-_NN OH-cholesterol_NNP for_IN 12_CD hours_NNS ,_, then_RB processed_VBN for_IN
          Western_JJ blot_NN analyses_NNS ._. Antibodies_NNP against_IN c-jun_JJ ,_,
          phospho-c-jun_JJ (_( at_IN position_NN serine_NN 63_CD )_) or_CC ERK_NNP 1_CD /_NN 2_CD (_( an_DT
          antibody_NN which_WDT can_MD recognize_VB both_DT ERK_NNP 1_CD and_CC ERK_NNP 2_LS )_) were_VBD
          used_VBN in_IN this_DT set_JJ of_IN experiments_NNS ._. Results_NNS indicated_VBD that_IN
          both_DT cholesterol_NN oxides_NNS caused_VBD an_DT increase_NN in_IN c-jun_JJ in_IN
          microglia_NN ,_, with_IN 25_CD -_: OH-cholesterol_NNP showing_VBG a_DT more_RBR
          pronounced_JJ increase_NN (_( Fig_NNP ._. 3_LS )_) ._. Furthermore_RB ,_,
          25_CD -_: OH-cholesterol_NNP caused_VBD the_DT phosphorylation_NN of_IN c-jun_JJ ,_, a_DT
          phenomenon_NN not_RB observed_VBD in_IN 7_CD -_: β-_NN OH-cholesterol_NNP treated_VBD
          microglia_NN ._. The_DT levels_NNS of_IN ERK_NNP 1_CD /_NN 2_CD were_VBD not_RB altered_VBN by_IN
          either_DT treatment_NN ._. These_DT results_NNS suggested_VBD that_IN c-jun_JJ
          activation_NN was_VBD associated_VBN with_IN the_DT toxicity_NN of_IN
          cholesterol_NN oxides_NNS ._.
          A_DT set_NN of_IN experiments_NNS was_VBD performed_VBN to_TO determine_VB any_DT
          dose-dependent_JJ change_NN in_IN c-jun_JJ activation_NN by_IN
          25_CD -_: OH-cholesterol_NNP ._. Microglia_NNP were_VBD treated_VBN with_IN 0_CD ,_, 1_CD ._. 25_CD ,_,
          2_CD ._. 5_CD ,_, 5_CD ,_, 10_CD or_CC 20_CD μM_NN 25_CD -_: OH-cholesterol_NNP for_IN 12_CD hours_NNS ,_, then_RB
          processed_VBN for_IN Western_JJ blot_NN analysis_NN ._. Results_NNS indicated_VBD
          that_IN 25_CD -_: OH-cholesterol_NNP treatment_NN led_VBN to_TO an_DT increase_NN in_IN
          c-jun_JJ and_CC phospho-c-jun_JJ at_IN serine_NN 63_CD ._. The_DT levels_NNS of_IN ERK_NNP
          1_CD /_NN 2_CD were_VBD not_RB altered_VBN by_IN this_DT treatment_NN (_( Fig_NNP ._. 4_LS )_) ._.
        
        
          Time-dependent_NNP change_NN of_IN MAP_NNP kinase_NN
          activities_NNS
          Further_RB studies_VBZ were_VBD performed_VBN to_TO determine_VB the_DT effect_NN
          of_IN 25_CD -_: OH-cholesterol_NNP on_IN different_JJ members_NNS of_IN MAP_NNP kinases_NNS ._.
          The_DT time-dependent_JJ change_NN in_IN c-jun_JJ ,_, ERK_NNP and_CC p_NN 38_CD levels_NNS
          was_VBD determined_VBN ._. Cells_NNP were_VBD treated_VBN with_IN 10_CD μM_NN
          25_CD -_: OH-cholesterol_NNP for_IN 1_CD ,_, 3_CD ,_, 6_CD ,_, 12_CD or_CC 24_CD hours_NNS ,_, then_RB
          processed_VBN for_IN Western_JJ blot_NN analyses_NNS ._. Results_NNS indicated_VBD
          that_IN there_EX was_VBD an_DT increase_NN in_IN c-jun_JJ after_IN
          25_CD -_: OH-cholesterol_NNP treatment_NN between_IN 1_CD -_: 12_CD hours_NNS of_IN
          treatment_NN ._. This_DT protein_NN dropped_VBD to_TO a_DT non-detectable_JJ level_NN
          at_IN 24_CD hours_NNS after_IN treatment_NN ._. In_IN addition_NN ,_, there_EX was_VBD an_DT
          increase_NN in_IN the_DT levels_NNS of_IN phospho-c-jun_JJ on_IN the_DT serine_NN
          residues_NNS (_( at_IN both_DT position_NN 63_CD and_CC position_NN 73_CD )_) ._. The_DT
          levels_NNS of_IN JNK_NNP (_( JNK_NNP 1_CD and_CC JNK_NNP 2_LS )_) ,_, however_RB ,_, were_VBD not_RB
          altered_VBN (_( Fig_NNP ._. 5_LS )_) ._.
          The_DT levels_NNS of_IN ERK_NNP 1_CD /_NN 2_CD were_VBD similar_JJ during_IN the_DT first_JJ 6_CD
          hours_NNS ,_, then_RB dropped_VBD between_IN 12_CD -_: 24_CD hours_NNS after_IN treatment_NN ._.
          The_DT levels_NNS of_IN phospho-_NN ERK_NNP increased_VBD between_IN 1_CD -_: 6_CD hours_NNS
          after_IN treatment_NN ,_, then_RB decreased_VBD to_TO a_DT non-detectable_JJ level_NN
          afterwards_RB (_( Fig_NNP ._. 5_LS )_) ._. This_DT decrease_NN in_IN phospho-_NN ERK_NNP
          expression_NN occurred_VBD at_IN a_DT time_NN coincided_VBD with_IN the_DT
          appearance_NN of_IN phospho-c-jun_JJ ._. The_DT changes_NNS in_IN p_NN 38_CD or_CC
          phospho-p_JJ 38_CD levels_NNS were_VBD minimal_JJ (_( Fig_NNP ._. 5_LS )_) ._.
        
        
          Modulation_NNP of_IN c-jun_JJ activation_NN by_IN PPAR_NNP
          agonists_NNS
          It_PRP was_VBD reported_VBN that_IN PPAR_NNP activation_NN could_MD
          down-regulate_JJ the_DT activity_NN of_IN AP-_NNP 1_CD by_IN interfering_VBG with_IN
          the_DT functions_NNS of_IN c-jun_JJ [_NN 36_CD 37_CD ]_NN ._. Therefore_RB ,_, the_DT
          following_VBG set_NN of_IN experiments_NNS was_VBD designed_VBN to_TO test_VB if_IN PPAR_NNP
          activation_NN could_MD reduce_VB c-jun_JJ activation_NN in_IN
          25_CD -_: OH-cholesterol_NNP treated_VBD microglia_NN ._. PPAR_NNP agonists_NNS
          including_VBG the_DT prostaglandin_NN ,_, 15_CD d-_NN PGJ_NNP 
          2_CD ,_, and_CC two_CD non-steroid_JJ
          anti-inflammatory_JJ drugs_NNS ,_, indomethacin_NN and_CC ibuprofen_NN ,_, were_VBD
          tested_VBN in_IN this_DT series_NN of_IN experiments_NNS ._. Cells_NNP were_VBD treated_VBN
          with_IN 5_CD μM_NN 25_CD -_: OH-cholesterol_NNP together_RB with_IN these_DT PPAR_NNP
          agonists_NNS for_IN 12_CD hours_NNS ,_, then_RB processed_VBN for_IN Western_JJ blot_NN
          analyses_NNS ._. Antibodies_NNP against_IN c-jun_JJ ,_, phospho-c-jun_JJ (_( at_IN
          serine_NN 63_CD )_) and_CC ERK_NNP 1_CD /_NN 2_CD were_VBD used_VBN in_IN this_DT set_JJ of_IN
          experiments_NNS ._. Results_NNS indicated_VBD that_IN while_IN
          25_CD -_: OH-cholesterol_NNP induced_VBD the_DT expression_NN of_IN c-jun_JJ and_CC
          phospho-c-jun_JJ ,_, these_DT PPAR_NNP agonists_NNS reduced_VBD the_DT expression_NN
          to_TO various_JJ degrees_NNS ._. The_DT apparent_JJ potency_NN to_TO reduce_VB
          phospho-c-jun_JJ among_IN the_DT three_CD agents_NNS tested_VBN was_VBD :_: 15_CD d-_NN PGJ_NNP 
          2_CD >_NN indomethacin_NN >_NN ibuprofen_NN
          (_( Fig_NNP ._. 6_CD )_) ._. These_DT results_NNS indicated_VBD that_IN while_IN 15_CD d-_NN PGJ_NNP 
          2_CD was_VBD very_RB effective_JJ in_IN inhibiting_VBG
          c-jun_JJ activation_NN ,_, ibuprofen_NN appeared_VBD to_TO be_VB ineffective_JJ in_IN
          this_DT regard_NN ._.
        
        
          PPAR_NNP agonists_NNS attenuate_NN cholesterol_NN oxide_NN induced_VBD
          cytotoxicity_NN in_IN microglia_NN
          Since_IN PPAR_NNP agonists_NNS appeared_VBD to_TO reduce_VB the_DT c-jun_JJ
          activation_NN caused_VBN by_IN 25_CD -_: OH-cholesterol_NNP treatment_NN ,_, the_DT
          following_VBG experiment_NN was_VBD designed_VBN to_TO test_VB if_IN these_DT agents_NNS
          could_MD reduce_VB 25_CD -_: OH-cholesterol_NNP induced_VBD cytotoxicity_NN ._.
          Cells_NNP were_VBD treated_VBN with_IN 5_CD μM_NN 25_CD -_: OH-cholesterol_NNP together_RB
          with_IN PPAR_NNP agonists_NNS to_TO be_VB tested_VBN for_IN 2_CD days_NNS ,_, then_RB the_DT
          viability_NN of_IN each_DT treatment_NN was_VBD determined_VBN ._. Results_NNS
          indicated_VBD that_IN 15_CD d-_NN PGJ_NNP 
          2_CD could_MD prevent_VB 25_CD -_: OH-cholesterol_NNP
          induced_VBD cell_NN death_NN in_IN a_DT dose-dependent_JJ manner_NN ._. While_IN
          treatment_NN of_IN the_DT cells_NNS with_IN 5_CD μM_NN 25_CD -_: OH-cholesterol_NNP
          reduced_VBD the_DT cell_NN viability_NN to_TO ~_NN 7_CD %_NN of_IN controls_NNS ,_, addition_NN
          of_IN 0_CD ._. 62_CD ,_, 1_CD ._. 25_CD ,_, 2_CD ._. 5_CD ,_, 5_CD or_CC 10_CD μM_NN 15_CD d-_NN PGJ_NNP 
          2_CD raised_VBD the_DT viabilities_NNS to_TO ~_NN 10_CD ,_, 14_CD ,_,
          18_CD ,_, 34_CD or_CC 48_CD %_NN ,_, respectively_RB (_( Fig_NNP ._. 7_CD )_) ._. The_DT rescue_NN by_IN 5_CD μM_NN
          and_CC 10_CD μM_NN 15_CD d-_NN PGJ_NNP 
          2_CD was_VBD statistically_RB significant_JJ (_( p_NN
          <_NN 0_CD ._. 001_CD )_) ._. This_DT agent_NN at_IN concentrations_NNS above_IN 10_CD μM_NN was_VBD
          toxic_JJ to_TO microglia_NN ._. The_DT solvent_JJ for_IN 15_CD d-_NN PGJ_NNP 
          2_CD ,_, methylacetate_NN ,_, was_VBD without_IN any_DT
          rescue_NN effect_NN ._.
          Indomethacin_NNP also_RB prevented_VBD 25_CD -_: OH-cholesterol_NNP induced_VBD
          cell_NN death_NN in_IN a_DT dose-dependent_JJ manner_NN (_( Fig_NNP ._. 8_CD )_) ._. This_DT
          agent_NN at_IN 12_CD ._. 5_LS ,_, 25_CD ,_, 50_CD ,_, or_CC 100_CD μM_NN raised_VBD the_DT viability_NN
          from_IN ~_NN 8_CD %_NN to_TO ~_NN 11_CD ,_, 13_CD ,_, 19_CD or_CC 31_CD %_NN of_IN controls_NNS ,_, respectively_RB ._.
          A_DT further_JJ increase_NN in_IN indomethacin_NN to_TO 200_CD μM_NN did_VBD not_RB
          increase_VB cell_NN viability_NN ._. The_DT rescue_NN by_IN 50_CD -_: 200_CD μM_NN
          indomethacin_NN was_VBD statistically_RB significant_JJ (_( p_NN <_NN
          0_CD ._. 001_CD )_) ._. Ibuprofen_NNP ,_, on_IN the_DT other_JJ hand_NN ,_, had_VBD little_JJ rescue_NN
          effect_NN even_RB at_IN 200_CD μM_NN (_( Fig_NNP ._. 9_CD )_) ._. It_PRP is_VBZ important_JJ to_TO note_VB
          that_IN this_DT agent_NN also_RB had_VBD no_DT inhibitory_NN effect_NN on_IN c-jun_JJ
          activation_NN (_( Fig_NNP ._. 6_CD )_) ._.
          While_IN 15_CD d-_NN PGJ_NNP 
          2_CD is_VBZ considered_VBN to_TO be_VB a_DT PPARγ_NNP agonist_NN ,_,
          indomethacin_NN and_CC ibuprofen_NN can_MD activate_VBP both_DT PPARγ_NNP and_CC
          PPARα_NNP [_NN 27_CD ]_NN ._. The_DT following_VBG experiment_NN was_VBD conducted_VBN to_TO
          determine_VB if_IN a_DT pure_JJ PPARα_NNP agonist_NN ,_, WY_NNP 14643_CD ,_, could_MD
          modulate_VBP the_DT 25_CD -_: OH-cholesterol_NNP induced_VBD cytotoxicity_NN ._.
          Results_NNS indicated_VBD that_IN this_DT agent_NN was_VBD without_IN rescue_NN
          effect_NN at_IN 25_CD ,_, 50_CD or_CC 100_CD μM_NN ._. At_IN 200_CD μM_NN ,_, WY_NNP 14643_CD raised_VBD the_DT
          viability_NN from_IN ~_NN 10_CD %_NN to_TO ~_NN 28_CD %_NN of_IN controls_NNS ._. The_DT difference_NN
          was_VBD statistically_RB significant_JJ (_( p_NN <_NN 0_CD ._. 001_CD )_) ._. No_DT further_JJ
          increase_NN in_IN viability_NN could_MD be_VB achieved_VBN by_IN this_DT agent_NN
          (_( Fig_NNP ._. 10_CD )_) ._.
          Since_IN 25_CD -_: OH-cholesterol_NNP induced_VBD an_DT alteration_NN of_IN
          phospho-_NN ERK_NNP 1_CD /_NN 2_CD during_IN the_DT first_JJ 6_CD hours_NNS of_IN treatment_NN
          (_( Fig_NNP ._. 5_LS )_) ,_, an_DT experiment_NN was_VBD performed_VBN to_TO test_VB if_IN
          inhibition_NN of_IN ERK_NNP pathways_NNS could_MD affect_VB 25_CD -_: OH-cholesterol_NNP
          induced_VBD cell_NN death_NN ._. Microglia_NNP were_VBD treated_VBN with_IN 5_CD μM_NN
          25_CD -_: OH-cholesterol_NNP together_RB with_IN 10_CD μM_NN AG_NNP 126_CD (_( ERK_NNP
          inhibitor_NN )_) ,_, PD_NNP 98059_CD (_( MEK_NNP inhibitor_NN ,_, an_DT up-stream_JJ member_NN
          in_IN the_DT ERK_NNP pathway_NN )_) for_IN 2_CD days_NNS ,_, then_RB the_DT viability_NN of_IN
          each_DT treatment_NN was_VBD determined_VBN ._. Results_NNS indicated_VBD that_IN
          neither_DT of_IN the_DT pharmacological_JJ agents_NNS tested_VBN had_VBD any_DT
          rescue_NN effect_NN toward_IN 25_CD -_: OH-cholesterol_NNP induced_VBD
          cytotoxicity_NN ._. Similarly_RB ,_, the_DT p_NN 38_CD pathway_NN inhibitor_NN ,_,
          SB_NNP 203580_CD ,_, had_VBD no_DT rescue_NN effect_NN under_IN the_DT same_JJ
          experimental_JJ conditions_NNS (_( results_NNS not_RB shown_VBN )_) ._.
        
      
      
        Discussion_NNP
        Cholesterol_NNP oxides_NNS are_VBP formed_VBN in_IN cholesterol-containing_JJ
        food_NN (_( powdered_JJ milk_NN ,_, cheese_NN ,_, egg_NN products_NNS )_) during_IN storage_NN [_NN
        38_CD 39_CD ]_NN or_CC during_IN cholesterol_NN catabolism_NN in_IN animals_NNS [_NN 40_CD ]_NN
        ._. The_DT level_NN of_IN cholesterol_NN oxide_NN in_IN meat_NN product_NN increases_NNS
        significantly_RB during_IN the_DT cooking_NN process_NN [_NN 39_CD ]_NN ._. Animals_NNS
        can_MD take_VB up_RP cholesterol_NN oxides_NNS in_IN a_DT way_NN similar_JJ to_TO the_DT
        absorption_NN of_IN cholesterol_NN ._. Cholesterol_NNP oxides_NNS given_VBN
        exogenously_RB can_MD be_VB cleared_VBN from_IN plasma_NN rapidly_RB and_CC be_VB
        widely_RB redistributed_JJ in_IN different_JJ parts_NNS of_IN the_DT body_NN [_NN 41_CD ]_NN
        ._. Cholesterol_NNP oxides_NNS and_CC authentic_JJ cholesterol_NN are_VBP
        transported_VBN within_IN the_DT cell_NN by_IN a_DT similar_JJ mechanism_NN ,_, but_CC the_DT
        transport_NN is_VBZ more_RBR efficient_JJ for_IN cholesterol_NN oxides_NNS [_NN 42_CD ]_NN ._.
        High_NNP levels_NNS of_IN cholesterol_NN oxides_NNS have_VBP been_VBN observed_VBN in_IN
        hypercholesterolemic_JJ animals_NNS ._. For_IN example_NN ,_, the_DT plasma_NN level_NN
        of_IN 7_CD -_: OH-cholesterol_NNP increases_NNS from_IN 15_CD μM_NN to_TO approximately_RB
        200_CD μM_NN in_IN rabbits_NNS fed_VBN with_IN high_JJ cholesterol_NN diet_NN for_IN 6_CD
        weeks_NNS [_NN 43_CD ]_NN ._.
        Cholesterol_NNP oxide_NN treatment_NN can_MD lead_VB to_TO alterations_NNS of_IN
        cellular_JJ functions_NNS ._. These_DT compounds_NNS can_MD activate_VBP some_DT
        nuclear_JJ receptors_NNS including_VBG steroidogenic_JJ factor_NN 1_CD [_NN 44_CD ]_NN
        and_CC LXR_NNP ,_, which_WDT may_MD be_VB partially_RB responsible_JJ for_IN their_PRP$
        biological_JJ activities_NNS [_NN 45_CD 46_CD ]_NN ._. Cholesterol_NNP oxides_NNS are_VBP
        inhibitors_NNS of_IN HMG-CoA_NNP reductase_NN ,_, the_DT key_JJ enzyme_NN of_IN
        cholesterol_NN biosynthesis_NNS pathway_NN [_NN 47_CD ]_NN ._. The_DT ability_NN to_TO
        bind_NN to_TO an_DT intracellular_NN receptor_NN ,_, oxysterol_NN binding_JJ
        protein_NN ,_, may_MD be_VB responsible_JJ for_IN their_PRP$ inhibition_NN of_IN
        cholesterol_NN biosynthesis_NNS [_NN 48_CD 49_CD ]_NN ._. It_PRP should_MD be_VB noted_VBN
        that_DT addition_NN of_IN cholesterol_NN does_VBZ not_RB prevent_VB cholesterol_NN
        oxide_NN induced_VBD cell_NN death_NN ,_, which_WDT leads_VBZ to_TO the_DT suggestion_NN
        that_DT inhibition_NN of_IN cholesterol_NN synthesis_NN is_VBZ not_RB the_DT cause_NN
        of_IN cholesterol_NN oxide_NN induced_VBD PCD_NNP [_NN 50_CD 51_CD ]_NN ._. The_DT critical_JJ
        events_NNS that_WDT result_NN in_IN cholesterol_NN oxide_NN induced_VBD
        cytotoxicity_NN remain_VB to_TO be_VB determined_VBN ._.
        Results_NNS from_IN this_DT study_NN indicated_VBD that_IN 25_CD -_: OH-cholesterol_NNP
        was_VBD very_RB cytotoxic_JJ to_TO microglia_NN ,_, such_JJ that_IN a_DT 2_CD -_: day_NN
        treatment_NN with_IN 5_CD μM_NN 25_CD -_: OH-cholesterol_NNP reduced_VBD cell_NN
        viability_NN to_TO 5_CD -_: 10_CD %_NN of_IN controls_NNS ._. In_IN contrast_NN ,_,
        7_CD -_: β-_NN OH-cholesterol_NNP was_VBD much_RB less_RBR toxic_JJ to_TO microglia_NN (_( Fig_NNP ._.
        1_LS ,_, 2_LS )_) ._. Selective_NNP toxicity_NN of_IN cholesterol_NN oxides_NNS toward_IN a_DT
        particular_JJ cell_NN type_NN was_VBD also_RB observed_VBN in_IN our_PRP$ previous_JJ
        studies_NNS [_NN 29_CD 31_CD 32_CD 33_CD ]_NN ._. Further_RB experiments_NNS with_IN Western_JJ
        blot_NN analyses_NNS indicated_VBD that_IN the_DT cytotoxicity_NN of_IN
        cholesterol_NN oxides_NNS was_VBD associated_VBN with_IN their_PRP$ abilities_NNS to_TO
        cause_VB c-jun_JJ activation_NN ,_, as_IN evidenced_VBN by_IN the_DT increase_NN in_IN
        activated_VBN c-jun_JJ ,_, i_NNP ._. e_SYM ._. ,_, phospho-c-jun_JJ ,_, in_IN 25_CD -_: OH-cholesterol_NNP
        treated_VBD cells_NNS but_CC not_RB in_IN 7_CD -_: β-_NN OH-cholesterol_NNP treated_VBD cells_NNS
        (_( Fig_NNP ._. 3_LS )_) ._. There_EX was_VBD a_DT dose-dependent_JJ increase_NN in_IN c-jun_JJ
        activation_NN in_IN cells_NNS treated_VBN with_IN 25_CD -_: OH-cholesterol_NNP (_( Fig_NNP ._.
        4_LS )_) ._.
        It_PRP has_VBZ been_VBN suggested_VBN that_IN a_DT dysregulation_NN of_IN MAP_NNP
        kinases_NNS is_VBZ responsible_JJ for_IN the_DT growth_NN factor_NN deprivation_NN [_NN
        15_CD ]_NN or_CC chemotherapeutic_JJ agent_NN [_NN 16_CD ]_NN induced_VBD PCD_NNP ._.
        Consistent_NNP with_IN this_DT idea_NN ,_, results_NNS from_IN this_DT study_NN suggest_VBP
        that_IN an_DT unfavorable_JJ balance_NN of_IN the_DT JNK_NNP and_CC ERK_NNP causes_VBZ the_DT
        cell_NN death_NN observed_VBD in_IN cholesterol_NN oxide_NN treated_VBD microglia_NN ._.
        Cells_NNP treated_VBD with_IN 25_CD -_: OH-cholesterol_NNP showed_VBD a_DT
        time-dependent_JJ increase_NN in_IN c-jun_JJ protein_NN as_RB well_RB as_IN
        phospho-c-jun_JJ (_( Fig_NNP ._. 5_LS )_) ._. This_DT c-jun_JJ activation_NN was_VBD apparent_JJ
        at_IN 6_CD hours_NNS after_IN treatment_NN ._. In_IN contrast_NN ,_, 25_CD -_: OH-cholesterol_NNP
        caused_VBD a_DT slight_JJ ,_, initial_JJ increase_NN in_IN phospho-_NN ERK_NNP ,_, which_WDT
        decreased_VBD to_TO a_DT non-detectable_JJ level_NN 6_CD hours_NNS after_IN
        treatment_NN ._. The_DT change_NN in_IN p_NN 38_CD and_CC phospho-p_JJ 38_CD ,_, on_IN the_DT other_JJ
        hand_NN ,_, was_VBD not_RB as_IN apparent_JJ ._. It_PRP was_VBD reported_VBN that_IN rabbits_NNS fed_VBN
        with_IN high-cholesterol_JJ diet_NN exhibited_VBN high_JJ JNK_NNP protein_NN
        levels_NNS and_CC JNK_NNP activity_NN in_IN their_PRP$ atherosclerotic_JJ lesions_NNS ,_,
        and_CC oxidized_JJ LDL_NNP caused_VBD JNK_NNP activation_NN in_IN cultured_JJ smooth_JJ
        muscle_NN cells_NNS [_NN 18_CD ]_NN ._. Based_VBN on_IN this_DT study_NN ,_, there_EX is_VBZ a_DT
        possibility_NN that_IN cholesterol_NN oxides_NNS in_IN oxidized_JJ LDL_NNP were_VBD
        responsible_JJ for_IN those_DT previous_JJ observations_NNS ._.
        Activation_NNP of_IN the_DT JNK_NNP pathway_NN can_MD lead_VB to_TO the_DT
        phosphorylation_NN of_IN downstream_JJ members_NNS including_VBG c-jun_JJ that_WDT
        belongs_VBZ to_TO the_DT AP-_NNP 1_CD transcription_NN factor_NN family_NN [_NN 12_CD 52_CD ]_NN ._.
        Because_IN results_NNS from_IN this_DT study_NN indicated_VBD that_IN JNK_NNP pathway_NN
        was_VBD activated_VBN by_IN 25_CD -_: OH-cholesterol_NNP ,_, one_PRP could_MD expect_VB that_IN
        AP-_NNP 1_CD would_MD be_VB activated_VBN in_IN cells_NNS treated_VBN with_IN cholesterol_NN
        oxides_NNS ._. Consistent_NNP with_IN this_DT idea_NN ,_, it_PRP was_VBD shown_VBN that_IN LDL_NNP
        could_MD induce_VB AP-_NNP 1_CD activity_NN in_IN endothelial_NN cells_NNS [_NN 53_CD ]_NN and_CC
        cholesterol_NN oxide_NN treatment_NN could_MD lead_VB to_TO increased_VB AP-_NNP 1_CD
        DNA_NNP binding_JJ activity_NN and_CC AP-_NNP 1_CD dependent_JJ transcription_NN in_IN
        other_JJ cell_NN types_NNS [_NN 54_CD 55_CD ]_NN ._. Results_NNS from_IN this_DT study_NN ,_, thus_RB ,_,
        complemented_JJ and_CC extended_VBD the_DT findings_NNS of_IN those_DT
        reports_NNS ._.
        The_DT PPARγ_NNP agonist_NN ,_, 15_CD d-_NN PGJ_NNP 
        2_CD ,_, functions_NNS as_IN a_DT general_JJ inhibitor_NN of_IN
        microglial_NN functions_NNS [_NN 56_CD 57_CD 58_CD ]_NN ._. For_IN example_NN ,_, this_DT agent_NN
        inhibits_NNS the_DT expression_NN of_IN inducible_JJ nitric_JJ oxide_NN synthase_NN ,_,
        tumor_NN necrosis_NNS factor-α_JJ ,_, interleukin-_NN 1_CD β_NN and_CC major_JJ
        histocompatibility_NN complex_JJ class_NN II_NNP in_IN activated_VBN microglia_NN ._.
        Inhibition_NNP of_IN the_DT signal_NN transducer_NN and_CC activator_NN of_IN
        transcription_NN 1_CD (_( STAT-_NNP 1_LS )_) and_CC the_DT nuclear_JJ factor_NN kB_NN (_( NF-kB_NNP )_)
        may_MD be_VB partially_RB responsible_JJ for_IN the_DT inhibitory_NN effects_NNS ._.
        Results_NNS from_IN this_DT study_NN further_RBR indicated_VBD that_IN PPAR_NNP
        agonists_NNS could_MD reduce_VB c-jun_JJ activation_NN (_( Fig_NNP ._. 6_CD )_) ._. Given_VBN the_DT
        suggestion_NN that_IN an_DT up-regulation_JJ of_IN c-jun_JJ is_VBZ a_DT cause_NN of_IN PCD_NNP
        [_NN 15_CD 16_CD ]_NN ,_, a_DT reduction_NN in_IN c-jun_JJ activation_NN by_IN PPAR_NNP
        agonists_NNS should_MD attenuate_NN 25_CD -_: OH-cholesterol_NNP induced_VBD
        cytotoxicity_NN ._. Consistent_NNP with_IN this_DT idea_NN ,_, results_NNS from_IN this_DT
        study_NN indicated_VBD that_IN 15_CD d-_NN PGJ_NNP 
        2_CD ,_, indomethacin_NN and_CC WY_NNP 14643_CD could_MD
        attenuate_NN the_DT cytotoxicity_NN caused_VBN by_IN 25_CD -_: OH-cholesterol_NNP to_TO
        various_JJ degrees_NNS (_( Fig_NNP ._. 7_CD ,_, 8_CD ,_, 10_CD )_) ._. Since_IN the_DT protective_JJ
        effect_NN of_IN WY_NNP 14643_CD could_MD be_VB observed_VBN only_RB at_IN concentrations_NNS
        higher_JJR than_IN 200_CD μM_NN ,_, there_EX is_VBZ a_DT possibility_NN that_IN this_DT agent_NN
        acted_VBD on_IN the_DT PPARγ_NNP receptor_NN to_TO achieve_VB the_DT protection_NN ._.
        Similar_JJ protective_JJ roles_NNS of_IN PPAR_NNP agonists_NNS have_VBP been_VBN shown_VBN
        in_IN other_JJ nervous_JJ tissues_NNS ._. For_IN example_NN ,_, PPARγ_NNP agonists_NNS were_VBD
        shown_VBN to_TO protect_VB cytokine-induced_JJ PCD_NNP in_IN cerebellar_NN granule_NN
        cells_NNS [_NN 59_CD ]_NN ._. These_DT agents_NNS could_MD also_RB block_VB the_DT neurotoxic_JJ
        effects_NNS caused_VBN by_IN β-amyloid_JJ activated_VBN microglia_NN ,_, and_CC thus_RB
        might_MD be_VB beneficial_JJ in_IN the_DT treatment_NN of_IN Alzheimer_NNP 's_POS disease_NN
        [_NN 60_CD ]_NN ._. In_IN non-neuronal_JJ tissues_NNS ,_, PPARα_NNP activation_NN was_VBD
        shown_VBN to_TO suppress_VB both_DT spontaneous_JJ rat_NN hepatocyte_NN PCD_NNP and_CC
        the_DT PCD_NNP induced_VBN by_IN transforming_VBG growth_NN factor-β_JJ 1_CD [_NN 61_CD ]_NN
        ._.
      
      
        Conclusions_NNP
        Treatment_NNP of_IN microglia_NN with_IN 25_CD -_: OH-cholesterol_NNP caused_VBD an_DT
        induction_NN of_IN c-jun_JJ ,_, phospho-c-jun_JJ and_CC a_DT reduction_NN in_IN
        cellular_JJ viability_NN ._. PPAR_NNP agonists_NNS reduced_VBD the_DT
        25_CD -_: OH-cholesterol_NNP induced_VBD c-jun_JJ activation_NN and_CC attenuated_JJ
        the_DT cytotoxicity_NN ._. This_DT group_NN of_IN compounds_NNS may_MD be_VB useful_JJ in_IN
        future_JJ development_NN of_IN pharmacological_JJ agents_NNS against_IN
        cholesterol_NN oxide_NN induced_VBD cytotoxicity_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Cell_NNP culture_NN
          The_DT N_NNP 9_CD murine_NN microglia_NN cell_NN line_NN was_VBD a_DT gift_NN kindly_RB
          provided_VBN by_IN Dr_NNP ._. P_NN ._. Ricciardi-_NNP Castagnoli_NNP [_NN 62_CD ]_NN ._. This_DT
          cell_NN line_NN has_VBZ been_VBN used_VBN extensively_RB as_IN a_DT model_NN for_IN
          microglia_NN [_NN 63_CD 64_CD 65_CD ]_NN ._. These_DT cells_NNS were_VBD derived_VBN by_IN
          immortalization_NN of_IN day_NN 13_CD embryonic_JJ brain_NN cultures_NNS with_IN a_DT
          retrovirus_JJ carrying_NN an_DT activated_VBN v-myc_JJ oncogene_NN ._. The_DT
          cultures_NNS were_VBD maintained_VBN in_IN Minimum_NNP Essential_NNP Medium_NNP
          (_( MEM_NNP ,_, GibcoBRL_NNP ,_, Grand_NNP Island_NNP ,_, NY_NNP )_) supplemented_JJ with_IN 10_CD %_NN
          heat-inactivated_JJ fetal_JJ bovine_JJ serum_NN (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_,
          MO_NNP )_) ,_, 1_CD ._. 4_CD mM_NN glutamine_NN (_( GibcoBRL_NNP ,_, Grand_NNP Island_NNP ,_, NY_NNP )_) and_CC 20_CD
          μM_NN 2_CD -_: mercaptoethanol_NN (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP )_) ._. WY_NNP 14643_CD and_CC
          15_CD d-_NN PGJ_NNP 
          2_CD were_VBD purchased_VBN from_IN Cayman_NNP (_( Ann_NNP
          Arbor_NNP ,_, MI_NNP )_) ._. Indomethacin_NNP ,_, ibuprofen_NN and_CC all_DT other_JJ
          pharmacological_JJ and_CC general_JJ biochemical_JJ reagents_NNS were_VBD
          purchased_VBN from_IN Sigma_NNP (_( St_NNP ._. Louis_NNP ,_, MO_NNP )_) unless_IN otherwise_RB
          stated_VBN ._.
        
        
          Cell_NNP viability_NN
          Cells_NNP grown_VBN in_IN 96_CD -_: well_RB plates_NNS (_( 20_CD ,_, 000_CD cells_NNS /_NN well_RB ,_, ~_NN 90_CD %_NN
          confluency_NN )_) were_VBD treated_VBN with_IN testing_NN agents_NNS for_IN a_DT period_NN
          of_IN time_NN as_IN indicated_VBN in_IN the_DT figure_NN legends_NNS ;_: then_RB ,_, the_DT
          viability_NN from_IN each_DT treatment_NN was_VBD determined_VBN by_IN the_DT MTT_NNP
          (_( 3_CD -_: (_( 4_CD ,_, 5_CD -_: dimethylthiazole-_NN 2_CD yl_NN )_) -_: 2_CD ,_, 5_CD -_: diphenyltetrazolium_NN
          bromide_NN )_) assay_NN [_NN 66_CD ]_NN ._. Culture_NNP medium_NN was_VBD removed_VBN after_IN
          treatment_NN ,_, then_RB 100_CD μl_NN MTT_NNP solution_NN (_( 100_CD μg_NN /_NN ml_NN prepared_VBN
          in_IN MEM_NNP )_) was_VBD added_VBN to_TO each_DT well_RB ._. The_DT cultures_NNS were_VBD
          incubated_JJ at_IN 37_CD °_NN C_NNP for_IN one_CD hour_NN in_IN a_DT tissue_NN culture_NN
          incubator_NN ._. The_DT MTT_NNP solution_NN was_VBD then_RB removed_VBN ,_, and_CC the_DT
          cells_NNS in_IN each_DT well_RB were_VBD lysed_JJ by_IN the_DT addition_NN of_IN 100_CD μl_NN
          dimethly_RB sulfoxide_NN ._. The_DT plate_NN was_VBD placed_VBN on_IN a_DT shaker_NN for_IN
          one_CD hour_NN at_IN room_NN temperature_NN to_TO complete_VB the_DT lysing_VBG
          process_NN ,_, then_RB the_DT optical_JJ density_NN of_IN each_DT well_RB was_VBD
          measured_VBN by_IN a_DT 96_CD -_: well_RB plate_NN reader_NN with_IN a_DT filter_NN setting_VBG
          at_IN 570_CD nm_NN (_( reference_NN filter_NN setting_VBG was_VBD 630_CD nm_NN )_) ._.
        
        
          Western_JJ blot_NN analysis_NN
          Protein_NNP isolated_VBD from_IN cytoplasm_NN was_VBD separated_VBN by_IN
          SDS-PAGE_NNP on_IN 10_CD %_NN polyacrylamide_NN gels_NNS and_CC transferred_VBN to_TO
          nitrocellulose_NN membranes_NNS (_( NitroBind_NNP ,_, MSI_NNP ,_, Westborough_NNP ,_,
          MA_NNP )_) ,_, then_RB incubated_JJ with_IN primary_JJ antibody_NN overnight_JJ at_IN
          4_CD °_NN C_NNP ._. Specific_JJ bands_NNS were_VBD detected_VBN by_IN incubating_VBG the_DT
          membrane_NN with_IN horseradish_NN peroxidase_NN conjugated_JJ secondary_JJ
          antibody_NN for_IN 45_CD minutes_NNS at_IN room_NN temperature_NN ,_, then_RB with_IN
          ECL_NNP Western_NNP Blotting_NNP Detection_NNP Reagents_NNP (_( Amersham_NNP Life_NNP
          Science_NNP ,_, Arlington_NNP Heights_NNP ,_, IL_NNP )_) according_VBG to_TO the_DT
          manufacturer_NN 's_POS protocol_NN ._. The_DT primary_JJ antibodies_NNS used_VBN in_IN
          this_DT set_JJ of_IN experiments_NNS were_VBD from_IN New_NNP England_NNP Biological_NNP
          (_( anti-phospho-c-jun_JJ at_IN serine_NN 73_CD ,_, used_VBN at_IN 1_CD :_: 1000_CD )_) or_CC
          Santa_NNP Cruz_NNP (_( anti-c-jun_JJ ,_, used_VBN at_IN 1_CD :_: 3000_CD ;_:
          anti-phospho-c-jun_JJ at_IN serine_NN 63_CD ,_, used_VBN at_IN 1_CD :_: 1000_CD ,_,
          anti-_NN JNK_NNP ,_, used_VBN at_IN 1_CD :_: 3000_CD ;_: anti-_NN ERK_NNP 1_CD /_NN 2_CD ,_, used_VBN at_IN 1_CD :_: 3000_CD ;_:
          anti-phospho-_JJ ERK_NNP ,_, used_VBN at_IN 1_CD :_: 2000_CD ;_: anti-p_JJ 38_CD ,_, used_VBN at_IN
          1_CD :_: 3000_CD ;_: anti-phospho-p_JJ 38_CD ,_, used_VBN at_IN 1_CD :_: 1000_CD )_) ._.
        
        
          Statistical_NNP analysis_NN
          Unless_IN otherwise_RB stated_VBN ,_, results_NNS of_IN cell_NN viability_NN
          experiments_NNS were_VBD pooled_VBN from_IN 12_CD replicate_VB samples_NNS derived_VBN
          from_IN 3_CD independent_JJ experiments_NNS ,_, and_CC expressed_VBD as_IN mean_NN ±_NN
          SEM_NNP ._. Statistical_NNP analysis_NN was_VBD performed_VBN by_IN analysis_NN of_IN
          variance_NN (_( one-way_JJ ANOVA_NNP )_) followed_VBN by_IN the_DT Bonferroni_NNP test_NN
          to_TO determine_VB the_DT significance_NN of_IN difference_NN ._.
        
      
      
        List_NN of_IN abbreviations_NNS
        15_CD d-_NN PGJ_NNP 
        2_CD ,_, 15_CD -_: deoxy-delta_JJ 12_CD ,_, 14_CD -_: PGJ_NNP 
        2_CD ;_: AP-_NNP 1_CD ,_, activator_NN protein-_NN 1_CD ;_: ERK_NNP ,_,
        p_NN 42_CD /_NN 44_CD ,_, Extracellular_NNP signal-_NN Regulated_NNP Kinase_NNP ;_: LDL_NNP ,_, low_JJ
        density_NN lipoprotein_NN ;_: MAP_NNP kinases_NNS ,_, Mitogen-_NNP Activated_NNP Protein_NNP
        kinases_NNS ;_: MTT_NNP
        (_( 3_CD -_: (_( 4_CD ,_, 5_CD -_: dimethylthiazole-_NN 2_CD yl_NN )_) -_: 2_CD ,_, 5_CD -_: diphenyltetrazolium_NN
        bromide_NN )_) ;_: PCD_NNP ,_, programmed_VBN cell_NN death_NN ;_: PPARs_NNP ,_, peroxisome_NN
        proliferator-activated_JJ receptors_NNS ;_: SAPK_NNP /_NN JNK_NNP ,_,
        Stress-_NNP Activated_NNP Protein_NNP Kinase_NNP /_NN c-_NN Jun_NNP NH_NNP 2_CD -_: terminal_NN
        Kinase_NNP ._.
      
    
  
